E-Book | February 15, 2023

Gene, Cell, & RNA Therapy Landscape: Q4 2022 Data Report

Source: Citeline
GettyImages-583853208 Q4 report

In 2022, the gene, cell, and RNA therapy pipeline from preclinical to pre-registration grew by 7%, bringing the total number of therapies in development to 3,726. More than half (55%) of those are gene therapies, including genetically modified therapies like CAR T cell therapies. The remainder are non-genetically modified cell therapies (22%) and RNA therapies (23%).

In the gene therapy pipeline, oncology and rare diseases remain the top areas of development overall and in the clinic. Oncology and rare diseases are also the top areas of development in the overall pipeline of non-genetically modified cell therapies. Rare diseases and anti-infective therapies remain the top two targeted areas by RNA therapies.

Gain more insight from the 2022 fourth quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader